CCL7+ Macrophages Drive Immunotherapy Resistance in Colorectal Cancer

Study Background and Research Question

Colorectal cancer (CRC) is a leading cause of cancer-related morbidity and mortality worldwide. Although immune checkpoint inhibitors (ICIs), especially those targeting PD-1/PD-L1, have revolutionized treatment for certain molecular subtypes of CRC, notably those with high microsatellite instability (MSI-H) or defective mismatch repair (dMMR), overall response rates remain limited. Up to 50% of metastatic MSI-H/dMMR CRC patients exhibit resistance to immunotherapy, underscoring the urgent need to elucidate mechanisms of immune evasion and resistance to ICIs (Chen et al., 2025). The tumor microenvironment (TME), especially the role of tumor-associated macrophages (TAMs), has become a focus in understanding immune resistance. CCL7, a chemokine implicated in monocyte recruitment and tumor progression, has been observed to correlate with poor prognosis in various malignancies. However, its precise contribution to immunotherapy resistance in CRC remained unclear prior to this study.

Key Innovation from the Reference Study

The pivotal innovation of Chen et al. (2025) is the identification and mechanistic characterization of CCL7+ TAMs as key drivers of immunotherapy resistance in CRC. By integrating genetic ablation models, proteomic, transcriptomic, and flow cytometric analyses, the study demonstrates that myeloid-derived CCL7 orchestrates an immunosuppressive TME. This occurs through modulation of both macrophage metabolism and T-cell infiltration, positioning CCL7 as a promising combinatorial target alongside ICIs (Chen et al., 2025).

Methods and Experimental Design Insights

To dissect the role of CCL7 in the CRC immune microenvironment, the authors used a multi-pronged approach:

• Genetic Mouse Models: Ccl7 was specifically knocked out in myeloid cells using conditional knockout technology, and these mice were challenged with MC38 CRC cells to establish syngeneic tumor models.
• Proteomic and Transcriptomic Profiling: Tumor tissues were subjected to high-dimensional proteomic and RNA-seq analysis to identify CCL7-dependent regulatory networks.
• Flow Cytometry: Immune cell populations, including TAMs and CD8+ T cells, were quantitatively analyzed for infiltration and activation status.
• Functional Assays: Metabolic flux and chemokine analyses were performed to assess peroxisome biogenesis, fatty acid oxidation, and downstream chemokine expression (notably CXCL10).
• Therapeutic Blockade: The impact of CCL7 inhibition on tumor progression and responsiveness to anti-PD-L1 was evaluated using blocking antibodies.

Protocol Parameters

• mouse model | MC38 syngeneic tumor in Ccl7 myeloid-specific knockout mice | CRC immunotherapy resistance studies | Recapitulates TME dynamics and immune cell composition | paper
• flow cytometry panel | Multi-color, including F4/80, CD11b, CD8, activation markers | Immune cell subset quantification | Allows high-resolution analysis of TAM and T cell populations | paper
• anti-PD-L1 dosing | 10 mg/kg, intraperitoneally, 3x/week | Combination immunotherapy studies | Standardized for synergy assessment with CCL7 blockade | paper
• clodronate liposome dosing | 50-200 μl, route per model, per 20g mouse, 1-2x/week | Macrophage depletion in vivo | Enables targeted depletion of TAMs to probe immunosuppressive function | workflow_recommendation

Core Findings and Why They Matter

Chen et al. (2025) provide several mechanistically detailed insights:

• CCL7+ TAM Accumulation Correlates with ICI Resistance: CRC patient samples with high CCL7+ TAM infiltration displayed significantly lower response rates to ICIs (Chen et al., 2025).
• CCL7 Drives Immunosuppressive TAM Phenotype: CCL7 promotes peroxisome biogenesis and fatty acid oxidation in TAMs via the PI3K-AKT-PEX3 pathway, fostering their immunosuppressive functions.
• Inhibition of CD8+ T Cell Infiltration: CCL7 suppresses AKT2-STAT1-mediated CXCL10 expression, reducing recruitment of cytotoxic CD8+ T cells to the tumor microenvironment.
• Therapeutic Blockade of CCL7: Deletion or antibody-mediated blockade of CCL7 in myeloid cells not only diminished immunosuppressive TAMs but also increased activated CD8+ T cell infiltration, resulting in delayed CRC progression and enhanced efficacy of anti-PD-L1 therapy (Chen et al., 2025).

These findings position CCL7 as a dual regulator of both macrophage metabolism and adaptive immune cell exclusion, offering a new axis for combinatorial immunotherapy strategies.

Comparison with Existing Internal Articles

Recent internal resources provide a practical framework for leveraging macrophage depletion tools in immuno-oncology workflows:

• The article "Macrophage Depletion Reimagined: Translational Strategies..." contextualizes Clodronate Liposomes as a precision tool for in vivo macrophage depletion, emphasizing their application in dissecting TAM function and resistance mechanisms. This aligns directly with the reference study’s approach, where specific ablation of immunosuppressive macrophage populations is crucial for revealing their regulatory roles.
• "Clodronate Liposomes (K2721): Optimizing In Vivo Macrophage Depletion..." highlights workflow best practices and protocol optimization for reliably inducing apoptosis in macrophages, supporting robust immune modulation studies. The detailed technical guidance offered complements the reference paper’s translational insights.
• Finally, "Clodronate Liposomes: Precision Macrophage Depletion Reagent..." underscores the reagent’s compatibility with advanced cancer immunology models, echoing the reference paper's focus on precision immune cell modulation in vivo.

Collectively, these internal articles reinforce the mechanistic and translational value of selective macrophage depletion—whether via genetic ablation (as in the reference study) or reagent-based strategies (as detailed in the internal literature)—for unraveling TAM-driven immunotherapy resistance.

Limitations and Transferability

While the study robustly delineates CCL7 as a central mediator of ICI resistance in CRC, several limitations warrant consideration:

• Preclinical Focus: The primary evidence arises from murine models and ex vivo analyses. Although patient sample correlation was performed, direct clinical validation of CCL7-targeted strategies is pending.
• Specificity of Macrophage Subsets: The myeloid-specific Ccl7 knockout model may not capture the full heterogeneity of TAM populations or their plasticity in human disease.
• Pathway Complexity: The PI3K-AKT-PEX3 and AKT2-STAT1-CXCL10 axes are part of broader signaling networks; off-target effects and compensatory mechanisms could modulate therapeutic outcomes.

Despite these caveats, the mechanistic clarity achieved in this study provides a solid rationale for further translational and clinical exploration of CCL7 as a therapeutic target in CRC.

Research Support Resources

For researchers aiming to probe macrophage-mediated immunosuppression or model TME modulation in vivo, selective reagents are essential. Clodronate Liposomes (SKU K2721) from APExBIO encapsulate clodronate within liposomes, enabling precise depletion of macrophages through phagocytosis-mediated delivery and apoptosis induction. This tool is compatible with multiple administration routes and transgenic mouse models, facilitating tissue-specific studies of immune cell modulation and supporting workflows analogous to those described in the reference paper (workflow_recommendation). For protocol optimization and scenario-driven guidance, see recent internal articles on Clodronate Liposomes referenced above.